Lasofoxifene tartrateProduct ingredient for Lasofoxifene
- Name
- Lasofoxifene tartrate
- Drug Entry
- Lasofoxifene
Lasofoxifene is a non-steroidal 3rd generation selective estrogen receptor modulator (SERM) that selectively binds to both ERα and ERβ with high affinity. It is a naphthalene derivative marketed for prevention and treatment of osteoporosis and for the treatment of vaginal atrophy. It was initially developed as Oporia by Pfizer as a treatment for postmenopausal osteoporosis and vaginal atrophy, in which were both rejected for approval by FDA. Later Fablyn was developed as a result of a research collaboration between Pfizer and Ligand Pharmaceuticals with a newly submitted New Drug Application in 2008. It gained approval by European Commission in March 2009. Ligand Pharmaceuticals signed a license agreement with Sermonix Pharmaceuticals for the development and commercialization of oral lasofoxifene in the USA.
- Accession Number
- DBSALT001953
- Structure
Structure for Lasofoxifene tartrate (DBSALT001953)
- Synonyms
- Not Available
- External IDs
- CB-336156EB / CP-336156 / CP-336156-CB
- UNII
- 85X09V2GSO
- CAS Number
- 190791-29-8
- Weight
- Average: 563.647
Monoisotopic: 563.251917155 - Chemical Formula
- C32H37NO8
- InChI Key
- INEHJXCWEVNEDZ-LUDNRVPPSA-N
- InChI
- InChI=1S/C28H31NO2.C4H6O6/c30-24-11-15-27-23(20-24)10-14-26(21-6-2-1-3-7-21)28(27)22-8-12-25(13-9-22)31-19-18-29-16-4-5-17-29;5-1(3(7)8)2(6)4(9)10/h1-3,6-9,11-13,15,20,26,28,30H,4-5,10,14,16-19H2;1-2,5-6H,(H,7,8)(H,9,10)/t26-,28+;1-,2-/m10/s1
- IUPAC Name
- (2S,3S)-2,3-dihydroxybutanedioic acid; (5R,6S)-6-phenyl-5-{4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}-5,6,7,8-tetrahydronaphthalen-2-ol
- SMILES
- O[C@@H]([C@H](O)C(O)=O)C(O)=O.OC1=CC=C2[C@H]([C@H](CCC2=C1)C1=CC=CC=C1)C1=CC=C(OCCN2CCCC2)C=C1
- External Links
- ChemSpider
- 2339419
- Predicted Properties
Property Value Source Water Solubility 0.000398 mg/mL ALOGPS logP 6.36 ALOGPS logP 5.97 Chemaxon logS -6 ALOGPS pKa (Strongest Acidic) 10.21 Chemaxon pKa (Strongest Basic) 8.98 Chemaxon Physiological Charge 1 Chemaxon Hydrogen Acceptor Count 3 Chemaxon Hydrogen Donor Count 1 Chemaxon Polar Surface Area 32.7 Å2 Chemaxon Rotatable Bond Count 9 Chemaxon Refractivity 126.83 m3·mol-1 Chemaxon Polarizability 47.59 Å3 Chemaxon Number of Rings 5 Chemaxon Bioavailability 0 Chemaxon Rule of Five No Chemaxon Ghose Filter No Chemaxon Veber's Rule Yes Chemaxon MDDR-like Rule Yes Chemaxon